B. Riley Has Positive Outlook of ARWR FY2025 Earnings

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) – Analysts at B. Riley upped their FY2025 EPS estimates for Arrowhead Pharmaceuticals in a research report issued on Thursday, January 2nd. B. Riley analyst M. Mamtani now forecasts that the biotechnology company will earn $1.00 per share for the year, up from their previous forecast of $0.99. The consensus estimate for Arrowhead Pharmaceuticals’ current full-year earnings is ($3.79) per share.

Several other equities analysts have also recently weighed in on the company. HC Wainwright reiterated a “buy” rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Friday, December 20th. StockNews.com raised Arrowhead Pharmaceuticals to a “sell” rating in a report on Friday, December 20th. Piper Sandler decreased their price target on Arrowhead Pharmaceuticals from $62.00 to $45.00 and set an “overweight” rating on the stock in a research report on Wednesday, November 27th. Sanford C. Bernstein cut their price objective on shares of Arrowhead Pharmaceuticals from $27.00 to $24.00 and set a “market perform” rating for the company in a research report on Friday, November 29th. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and set a $42.00 target price on shares of Arrowhead Pharmaceuticals in a report on Thursday, September 26th. One analyst has rated the stock with a sell rating, four have assigned a hold rating and six have assigned a buy rating to the company. According to MarketBeat, Arrowhead Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $43.33.

Arrowhead Pharmaceuticals Stock Up 0.7 %

ARWR opened at $19.79 on Monday. The company has a market cap of $2.46 billion, a PE ratio of -3.94 and a beta of 0.97. The company has a 50 day moving average of $21.05 and a 200 day moving average of $22.64. Arrowhead Pharmaceuticals has a 12 month low of $17.05 and a 12 month high of $39.83. The company has a current ratio of 6.74, a quick ratio of 6.74 and a debt-to-equity ratio of 2.06.

Insiders Place Their Bets

In other news, CEO Christopher Richard Anzalone sold 26,712 shares of the business’s stock in a transaction dated Wednesday, December 18th. The stock was sold at an average price of $21.24, for a total value of $567,362.88. Following the completion of the sale, the chief executive officer now owns 3,688,335 shares of the company’s stock, valued at approximately $78,340,235.40. The trade was a 0.72 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director William D. Waddill sold 3,748 shares of the stock in a transaction dated Monday, December 16th. The shares were sold at an average price of $21.90, for a total value of $82,081.20. Following the sale, the director now owns 44,125 shares of the company’s stock, valued at $966,337.50. This represents a 7.83 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 45,873 shares of company stock valued at $952,553 over the last quarter. 4.50% of the stock is owned by corporate insiders.

Institutional Trading of Arrowhead Pharmaceuticals

Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Values First Advisors Inc. purchased a new stake in Arrowhead Pharmaceuticals during the 3rd quarter valued at $52,000. Meeder Asset Management Inc. boosted its holdings in shares of Arrowhead Pharmaceuticals by 4,629.2% during the second quarter. Meeder Asset Management Inc. now owns 3,405 shares of the biotechnology company’s stock worth $88,000 after purchasing an additional 3,333 shares during the period. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Arrowhead Pharmaceuticals by 21.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,496 shares of the biotechnology company’s stock worth $88,000 after purchasing an additional 788 shares during the last quarter. Quantbot Technologies LP bought a new position in Arrowhead Pharmaceuticals during the 3rd quarter valued at approximately $149,000. Finally, Quarry LP lifted its holdings in Arrowhead Pharmaceuticals by 54.5% in the 2nd quarter. Quarry LP now owns 8,500 shares of the biotechnology company’s stock worth $221,000 after buying an additional 3,000 shares during the period. Institutional investors own 62.61% of the company’s stock.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.